Table 1 Baseline demographic data between the two groups
Factors | Surviving groupv n = 11,911 | Nonsurviving group n = 2142 | Total n = 14,053 | p value |
|---|---|---|---|---|
Number (%) | Number (%) | Number (%) | ||
Sex | 0.385 | |||
Male | 8060 (67.7%) | 1429 (66.7%) | 9489 (67.5%) | |
Female | 3851 (32.3%) | 713 (33.3%) | 4564 (32.5%) | |
Age range, years | < 0.001 | |||
< 30 | 4671 (39.2%) | 378 (17.6%) | 5049 (35.9%) | |
30–49 | 5976 (50.2%) | 1267 (59.2%) | 7243 (51.5%) | |
≥ 50 | 1264 (10.6%) | 497 (23.2%) | 1761 (12.5%) | |
Mean ± SD | 34 ± 11 | 41 ± 12 | 35 ± 12 | |
Medical benefit schemes | < 0.001 | |||
UC | 7321 (62.1%) | 1543 (72.8%) | 8864 (63.7%) | |
SS | 4199 (35.6%) | 540 (25.5%) | 4739 (34.1%) | |
CSMBS | 271 (2.3%) | 36 (1.7%) | 307 (2.2%) | |
Total | 11,791 (100%) | 2119 (100%) | 13,910 (100%) | |
History of previous OIs prior to ART | < 0.001 | |||
No | 10,957 (92.0%) | 1801 (84.1%) | 12,758 (90.8%) | |
Yes | 954 (8.0%) | 341 (15.9%) | 1295 (9.2%) | |
OIs during ART | < 0.001 | |||
No | 10,995 (92.3%) | 1870 (87.3%) | 12,865 (91.5%) | |
Yes | 916 (7.7%) | 272 (12.7%) | 1188 (8.5%) | |
ART regimens | < 0.001 | |||
Efavirenz-containing | 7438 (82.6%) | 713 (76.9%) | 8151 (82.1%) | |
Nevirapine-containing | 1238 (13.7%) | 197 (21.3%) | 1435 (14.4%) | |
Lopinavir/ritonavir-containing | 328 (3.6%) | 17 (1.8%) | 345 (3.5%) | |
Total | 9004 (100.0%) | 927 (100.0%) | 9931 (100.0%) | |
Baseline CD4 count, cells/mm3 | < 0.001 | |||
≤200 | 3514 (52.1%) | 690 (80.5%) | 4204 (55.3%) | |
201–500 | 2385 (35.4%) | 135 (15.7%) | 2520 (33.2%) | |
> 500 | 846 (12.5%) | 32 (11.6%) | 878 (11.5) | |
Total | 6745 (100%) | 857 (100.0%) | 7602 (100.0%) | |
Median (IQR25th–75th) | 186 (51–367) | 50 (19–145) | 162 (44–353) | |
Time since registration to start ART, years | 0.305 | |||
Median (IQR25th–75th) | 0.06 (0.02–0.13) | 0.08 (0.04–0.16) | 0.06 (0.02–0.13) | |
ART switch during follow-up period | < 0.001 | |||
No | 6027 (64.4%) | 34 (14.2%) | 6061 (63.1%) | |
Yes | 3332 (35.6%) | 206 (85.8%) | 3538 (36.9%) | |
Total | 9359 (100.0%) | 240 (100.0%) | 9599 (100.0%) | |
Reasons to switch ART | 0.049 | |||
Complication | 1733 (52.0%) | 98 (47.6%) | 1831 (51.8%) | |
Treatment failure | 214 (6.4%) | 22 (10.7%) | 236 (6.7%) | |
Data not available | 1385 (41.6%) | 86 (41.7%) | 1471 (41.6%) | |
Total | 3332 (100.0%) | 206 (100.0%) | 3538 (100.0%) | |
Time to plasma HIV viral load < 40 copies/mL, years | ||||
Mean ± SD | 1.4 ± 0.5 | 1.4 ± 0.6 | 1.4 ± 0.5 | 0.811 |